⏳ Fetching live dividend data...
Home › Calculator › TRVN Dividend Calculator 2026
Trevena, Inc. · OTC
Price: $0.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in TRVN → $3.604679681910979e+44M in 10 years · $30,038,982,681,786,144,000,000,000,000,000,000,000,000,000,000,000.00/month
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open TRVN position with:
Real after-tax yield depends on where you live and how you hold TRVN.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 200000.00% | 199997.20% | $20,000,000 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 170000.00% | 169997.20% | $17,000,000 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 160000.00% | 159997.20% | $16,000,000 / yr |
| 🇬🇧 UK ISA | 0% | 200000.00% | 199997.20% | $20,000,000 / yr |
| 🇬🇧 UK Taxable | 8.75% | 182500.00% | 182497.20% | $18,250,000 / yr |
| 🇨🇦 TFSA | 0% | 200000.00% | 199997.20% | $20,000,000 / yr |
| 🇨🇦 CA Taxable | 25% | 150000.00% | 149997.20% | $15,000,000 / yr |
| 🇦🇺 Super (pension) | 15% | 170000.00% | 169997.20% | $17,000,000 / yr |
| 🇦🇺 AU Taxable | 30% | 140000.00% | 139997.20% | $14,000,000 / yr |
| 🇩🇪 DE Taxable | 26.375% | 147250.00% | 147247.20% | $14,725,000 / yr |
| 🇫🇷 FR Taxable | 30% | 140000.00% | 139997.20% | $14,000,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
TRVN pays quarterly — 4 times per year. Next ex-div: TBD.
How TRVN compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for TRVN sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Other | 2024-11-26 | 76 | $568.75 | $43.2K | ||
| F-InKind | 2024-10-08 | 20 | $1.47 | $29.00 | ||
| F-InKind | 2024-10-08 | 45 | $1.47 | $66.00 | ||
| F-InKind | 2024-10-08 | 144 | $1.47 | $212.00 | ||
| F-InKind | 2024-10-08 | 144 | $1.47 | $212.00 | ||
| F-InKind | 2024-10-08 | 532 | $1.47 | $782.00 | ||
| F-InKind | 2024-10-08 | 17 | $1.47 | $25.00 | ||
| F-InKind | 2024-10-08 | 41 | $1.47 | $60.00 | ||
| F-InKind | 2024-10-08 | 130 | $1.47 | $191.00 | ||
| F-InKind | 2024-10-08 | 130 | $1.47 | $191.00 |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the TRVN dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →